Crestor May Be Safer Than Other Statins, FDA Tells Public Citizen
This article was originally published in The Pink Sheet Daily
Executive Summary
There is no evidence to suggest Crestor (rosuvastatin) should be withdrawn because of its renal or muscle toxicity profiles, FDA says in its rejection of Public Citizen's petition. "For any degree of LDL-lowering, rosuvastatin is as safe, and may well be safer than, any other marketed statin with regard to muscle toxicity," FDA says.